These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35778330)

  • 1. Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle.
    Jäschke N; Büning H
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):667-685. PubMed ID: 35778330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.
    Lam AK; Frabutt D; Li L; Xiao W
    Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the adeno-associated virus capsid in gene transfer.
    Van Vliet KM; Blouin V; Brument N; Agbandje-McKenna M; Snyder RO
    Methods Mol Biol; 2008; 437():51-91. PubMed ID: 18369962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting AAV vectors to extrahepatic tissues.
    Asokan A; Shen S
    Mol Ther; 2023 Dec; 31(12):3371-3375. PubMed ID: 37805712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.
    Dudek AM; Pillay S; Puschnik AS; Nagamine CM; Cheng F; Qiu J; Carette JE; Vandenberghe LH
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Throughput
    Westhaus A; Cabanes-Creus M; Rybicki A; Baltazar G; Navarro RG; Zhu E; Drouyer M; Knight M; Albu RF; Ng BH; Kalajdzic P; Kwiatek M; Hsu K; Santilli G; Gold W; Kramer B; Gonzalez-Cordero A; Thrasher AJ; Alexander IE; Lisowski L
    Hum Gene Ther; 2020 May; 31(9-10):575-589. PubMed ID: 32000541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus serotypes for gene therapeutics.
    Lisowski L; Tay SS; Alexander IE
    Curr Opin Pharmacol; 2015 Oct; 24():59-67. PubMed ID: 26291407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms.
    Chen Q; Njenga R; Leuchs B; Chiocca S; Kleinschmidt J; Müller M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors.
    Macdonald J; Marx J; Büning H
    Hum Gene Ther; 2021 Oct; 32(19-20):1096-1119. PubMed ID: 34662226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.
    Dane AP; Wowro SJ; Cunningham SC; Alexander IE
    Gene Ther; 2013 Apr; 20(4):460-4. PubMed ID: 22895507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Analysis Full/Empty Capsid Ratio and Genome Integrity of Adeno-associated Virus (AAV) Gene Delivery Vectors.
    Hajba L; Guttman A
    Curr Mol Med; 2020; 20(10):806-813. PubMed ID: 32748744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights.
    Lopez-Gordo E; Chamberlain K; Riyad JM; Kohlbrenner E; Weber T
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
    Kwon I; Schaffer DV
    Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering adeno-associated virus vectors for gene therapy.
    Li C; Samulski RJ
    Nat Rev Genet; 2020 Apr; 21(4):255-272. PubMed ID: 32042148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications.
    Lugin ML; Lee RT; Kwon YJ
    ACS Nano; 2020 Nov; 14(11):14262-14283. PubMed ID: 33073995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosters for adeno-associated virus (AAV) vector (r)evolution.
    Szumska J; Grimm D
    Cytotherapy; 2023 Mar; 25(3):254-260. PubMed ID: 35999132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.